Unassociated Document
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON
D.C. 20549
_______________________
FORM
8-K
CURRENT
REPORT
Pursuant
to section 13 or 15(d) of the
Securities
exchange act of 1934
August
4, 2009
(Date of
earliest event reported)
ADVAXIS,
INC.
(Exact
name of registrant as specified in its charter)
Delaware
(State or
other jurisdiction of incorporation)
|
00028489
|
02-0563870
|
|
(Commission
File Number)
|
(IRS
Employer Identification Number)
|
| |
|
Technology
Centre of New Jersey
675
Rt. 1, Suite B113
North
Brunswick, N.J. 08902
(Address
of principal executive offices)
Registrant’s
telephone number, including area code: (732) 545-1590
Not
applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
8.01 Other Events
Advaxis,
Inc. (the “Company”) has been informed that its grant application filed with
Cancer Research UK, a leading cancer charity in the UK, for the use of
ADXS11-001 in the treatment of head and neck cancer, in collaboration with
investigators from Aintree Hospital (Liverpool), The Royal Marsden Hospital
(London), and Cardiff University, although well received by the New Agents
Committee, was not prioritized for funding at the present time. Given the level
of interest in the proposal, the New Agents Committee will contact the Company
should this situation change.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
|
|
| |
|
|
| Dated:
August 4, 2009 |
Advaxis,
Inc. |
|
| |
|
|
| |
|
|
|
|
|
By:
|
/s/ Thomas
A. Moore |
|
| |
|
Name:
Thomas A. Moore
Title: Chief
Executive Officer & Chairman of the Board
|
|
| |
|
|
|
| |
|
|
|